Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worldwide |
     
  2. Our Websites |
     
  3. Global Business Websites |
     
  4. Contact |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 
 
Sanofi Tuberculosis

Contact

Sanofi

Sanofi House
44 on Grand Central Office Park
2 Bond Street
Grand Central Extension 1
Midrand 16

Tel: +27 (0)11 256 3700
Fax: +27 (0)11 847 5099

If your question is related to an emergency, please consult your doctor or emergency unit.

Medical Information and Pharmacovigilance


Content :

Tuberculosis

TB is the No1. Cause of death in South African, this is a disgrace when you consider that it is a curable disease and the drugs are freely available at no cost to the patients in the public sector of South Africa. The cure rate targets set out by the WHO is 85% and the South African cure rates have improved from 67.8% in 2008 to 75.9% in 2012. It is therefore not surprising that SA HAS THE 3RD HIGHEST BURDEN IN THE WORLD and those with the highest burden are India & China (these also have the highest population than South Africa)respectively.

 

There are 3 aspects to TB Treatment:

  • Drug Susceptible (DS) TB treatment
  • Drug Resistant (DR) i.e. Multi and Extensively drug resistant (MDR & XDR) TB treatment
  • Preventative TB treatment (prophylaxis)

The Sanofi TB portfolio addresses all of these aspects with its portfolio of 6 products:

  • Rifafour & Rifinah
  • Terivalidin, Pyrazide and Ethatyl
  • Norstan - Isoniazid

The Sanofi Tuberculosis offers a comprehensive portfolio of drugs that can assists South Africans with addressing:

Defaulting, Relapse, and re-activation with various tools to complement the product range such as:

  • Providing tools to ensure HCP are equipped to make dosing simple, explain side effects, and be aware of drug interaction
  • Sponsor tools to follow up on defaulters
  • Support and encourage HCP’s with tools to make implementation of IPT treatment simple but effective
  • Provide tools to assist with identification of high risk environments where prophylactic treatment is necessary
  • Educate HCP’s on HIV concomitant therapy

These TB drugs are manufactured locally in Waltoo, near Mamelodi and currently exports accounts for 7% of the volumes including, Zambia/Angola/Mozambique/ Botswana/Namibia and Kenya. Plans to supply to the rest of the world are under way.

Updated June 20, 2013

Module :

SANOFI - A global integrated healthcare leader, focused on patients' needs

Sanofi South Africa - Corporate Presentation